Histone-lysine N-methyltransferase EZH2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Histone-lysine N-methyltransferase EZH2 shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q15910. Start with follicular lymphoma, then reuse UniProt Q15910 as the stable protein anchor across project notes and exports.
Start with follicular lymphoma, then reuse UniProt Q15910 as the stable protein anchor across project notes and exports.
Histone-lysine N-methyltransferase EZH2 shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with follicular lymphoma because it currently carries approved-linked support. Linked drugs include TAZEMETOSTAT HYDROBROMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHistone-lysine N-methyltransferase EZH2
Review this target as Histone-lysine N-methyltransferase EZH2, mapped to UniProt Q15910. Sequence length is 746 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Histone-lysine N-methyltransferase EZH2 as ChEMBL target CHEMBL2189110, mapped to UniProt Q15910. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Histone-lysine N-methyltransferase EZH2 is the right protein anchor across sources, using UniProt Q15910 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why follicular lymphoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Histone-lysine N-methyltransferase EZH2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q15910 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Histone-lysine N-methyltransferase EZH2 |
| UniProt Accession | Q15910 |
| Component Type | Protein |
| Sequence Length | 746 aa |
Histone-lysine N-methyltransferase EZH2
Review this target as Histone-lysine N-methyltransferase EZH2, mapped to UniProt Q15910. Sequence length is 746 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Histone-lysine N-methyltransferase EZH2 shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block.
Start review with follicular lymphoma because it currently carries approved-linked support. Linked drugs include TAZEMETOSTAT HYDROBROMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5188827 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL5172110 | 10.55 | IC50 | 0.028 | Preclinical |
| CHEMBL5178022 | 10.42 | IC50 | 0.038 | Preclinical |
| CHEMBL5206526 | 10.41 | IC50 | 0.039 | Preclinical |
| CHEMBL4639983 | 10.24 | IC50 | 0.057 | Preclinical |
| CHEMBL5188476 | 10.24 | IC50 | 0.057 | Preclinical |
| CHEMBL4640994 | 10.23 | IC50 | 0.059 | Preclinical |
| CHEMBL4638754 | 10.22 | IC50 | 0.06 | Preclinical |
| CHEMBL4637572 | 10.2 | IC50 | 0.063 | Preclinical |
| CHEMBL4635809 | 10.17 | IC50 | 0.067 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 350 | 194 | 7.1 |
| single protein format | 266 | 982 | 7.8 |
| assay format | 9 | 55 | 7.3 |
| subcellular format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 3 | 7.5 |
| cell-based format | 1 | 0 | — |
| organism-based format | 1 | 0 | — |